延迟细胞输注对接受 CAR-T 细胞治疗的大 B 细胞淋巴瘤患者的影响

Complications occurring after lymphodepleting chemotherapy (LDC) may delay chimeric antigen receptor (CAR) T-cell infusion. The effect of these delays on clinical outcomes is unclear.

We performed a retrospective analysis of 240 patients with relapsed/refractory large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel (axi-cel) and identified 40 patients (16. 7%) who had delay in axi-cel infusion. Of these, 85% had delay due to infection. At time of LDC initiation, patients with delayed infusion had lower absolute neutrophil count (P=0. 006), lower platelets (P=0. 004), lower hemoglobin (P<0. 001) and higher C-reactive protein (P=0. 001) than those with on-time infusion. Patients with delayed infusion had lower day 30 overall response rates (59. 0% vs. 79. 4%; P=0. 008) and shorter median progression-free survival (PFS) (3. 5 vs. 8.

2 months; P=0. 002) and overall survival (7. 8 vs. 26. 4 months; P=0. 046) than those with on-time infusion. The association with PFS was maintained on multivariate analysis. There was also an association between extent of delay and survival, with shorter median PFS in patients who had delays of 2-5 days (1. 8 vs. 8. 2 months; P=0.

001) and >5 days (4. 6 vs. 8. 2 months; P=0. 036), but not 1 day (5. 7 vs. 8. 2 months; P=0. 238). Following propensity score matching, patients with delayed infusion continued to have shorter median PFS (3. 5 vs. 6. 0 months; P=0. 015). Levels of pro-inflammatory cytokines on day of infusion were significantly higher in patients with delayed infusion.

Together, these findings suggest that delays in CAR T-cell administration after initiation of LDC are associated with inferior outcomes.

Further studies are needed to guide strategies to improve efficacy in such patients.